YAHOO FINANCE CHARTBOOK

44 charts that explain markets and the economy right now

Munich - Delayed Quote EUR

Sanofi SA (SNW2.MU)

50.50

+0.70

+(1.41%)

At close: January 28 at 8:14:38 AM GMT+1

No Tool

Measure

UNDO

Redo

All

All

Favorites

Text

Statistics

Technicals

Fibonacci

Markings

Lines

Annotation

Arrow

Line

Horizontal

Vertical

Rectangle

Trend Line

Measurement Line

Average Line

Callout

Channel

Check

Continuous

Crossline

Elliott Wave

Ellipse

Doodle

Fib Projection

Fib Arc

Fib Fan

Fib Time Zone

Focus

Gann Fan

Gartley

Heart

Pitchfork

Quadrant Lines

Ray

Regression Line

Fib Retracement

Star

Speed Resistance Arc

Speed Resistance Line

Time Cycle

Tirone Levels

Volume Profile

Cross

Loading Chart for SNW2.MU

Pharma Stock Roundup: JNJ's Q4 Earnings, FDA Nod to AZN, Daiichi Drug

Pharma Stock Roundup: JNJ's Q4 Earnings, FDA Nod to AZN, Daiichi Drug

Stocks to watch this week: ASML, Intel, LVMH, Shell and Glencore

Stocks to watch this week: ASML, Intel, LVMH, Shell and Glencore

SNY's Sarclisa Gets EU Nod for Expanded Use in Multiple Myeloma

SNY's Sarclisa Gets EU Nod for Expanded Use in Multiple Myeloma

FDA lifts hold on Opella’s trial to support switch of Cialis to OTC drug

FDA lifts hold on Opella’s trial to support switch of Cialis to OTC drug

Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma

Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma

Denali Gains 26.6% in a Year: How Should You Play the Stock?

Denali Gains 26.6% in a Year: How Should You Play the Stock?

Press Release: Opella reaches study milestone for Cialis

Press Release: Opella reaches study milestone for Cialis

SK bioscience and Sanofi’s GBP410 vaccine enters global Phase III trials

SK bioscience and Sanofi’s GBP410 vaccine enters global Phase III trials

Sanofi to increase competition in atopic dermatitis market after Dupixent success

Sanofi to increase competition in atopic dermatitis market after Dupixent success

Sanofi: Information concerning the total number of voting rights and shares – November 2024

Sanofi: Information concerning the total number of voting rights and shares – November 2024

SNY's Subcutaneous Sarclisa Proves Non-Inferior to IV Formulation (Revised)

SNY's Subcutaneous Sarclisa Proves Non-Inferior to IV Formulation (Revised)

1BAYN.MI Bayer Aktiengesellschaft

21.55

+0.49%

AZN.ST AstraZeneca PLC

1,536.00

+0.23%

NOV.DE Novo Nordisk A/S

82.26

-2.54%

ABBV AbbVie Inc.

174.81

-1.18%

PFE Pfizer Inc.

26.75

-0.41%

NVO Novo Nordisk A/S

85.19

-2.65%